Suppr超能文献

异维 A 酸暴露与妊娠结局:柏林临床胚胎学和妊娠药物风险评估研究所的一项观察性研究。

Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.

机构信息

Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie (BBGes), Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Spandauer Damm 130, Haus 10, 14050, Berlin, Germany.

出版信息

Arch Gynecol Obstet. 2010 Feb;281(2):221-7. doi: 10.1007/s00404-009-1112-2. Epub 2009 May 15.

Abstract

OBJECTIVE

Apart from thalidomide, retinoids like isotretinoin are the strongest teratogens in humans known today. The overall risk of birth defects is estimated as up to 30% after exposure during embryogenesis. In spite of well established pregnancy prevention programs, pregnancies still occur during isotretinoin therapy in many countries including Germany. A detailed investigation of the incidence and outcome of these pregnancies would fill an important gap.

METHODOLOGY

The Berlin Institute for Clinical Teratology documents prospectively the course of drug-exposed pregnancies when contacted for individual drug risk assessment. Datasets of isotretinoin exposed pregnancies recorded between 1993 and 2008 were evaluated as to the outcome of pregnancy.

RESULTS

A total of 108 pregnancies exposed to systemic isotretinoin (median dosage 20 mg/day) during the contraindicated period were registered. 76% (69/91) of the pregnancies with known outcome were electively terminated-mainly for fear of medication risk. No terminations due to abnormal prenatal ultrasound findings were reported. Spontaneous abortions occurred in five pregnancies. Of 18 live births including 1 pair of twins 1 major birth defect (small ventricular septal defect) was observed. None of the infants showed symptoms of retinoid embryopathy. 70% (48/69) of the patients with data on contraception did not use any method, in 30% contraception failed. There was no evidence that poor maternal education was a major cause for the omission of contraception documented in 48 women.

CONCLUSION

Inadvertent isotretinoin exposure during the first 2 weeks post conception does not necessarily require discussion of termination of pregnancy, as the risk of major birth defects appears to be much lower than it becomes beyond this period. Nevertheless, additional efforts are required to improve the effectiveness of contraception while on isotretinoin treatment considering psycho-social aspects such as improved self-confidence, unexpected new partnership and sexual activity and incorrect perception of infertility.

摘要

目的

除沙利度胺外,视黄酸类药物如异维 A 酸是目前已知的人类最强的致畸物。据估计,在胚胎发生期暴露后,出生缺陷的总体风险高达 30%。尽管有完善的妊娠预防计划,但在包括德国在内的许多国家,异维 A 酸治疗期间仍会发生妊娠。详细调查这些妊娠的发生率和结局将填补一个重要空白。

方法

柏林临床致畸学研究所通过接触进行个体药物风险评估来前瞻性地记录药物暴露妊娠的过程。评估了 1993 年至 2008 年间记录的异维 A 酸暴露妊娠的数据集,以了解妊娠结局。

结果

共登记了 108 例在禁忌期内接受全身异维 A 酸(中位数剂量 20mg/天)暴露的妊娠。69/91 例已知结局的妊娠中,76%(69/91)选择终止妊娠,主要是因为担心药物风险。没有因产前超声异常发现而终止妊娠的报告。5 例妊娠自然流产。18 例活产中,包括 1 对双胞胎,观察到 1 例主要出生缺陷(小室间隔缺损)。无婴儿出现视黄酸胚胎病的症状。48 例有避孕数据的患者中,70%(48/69)未使用任何方法,30%的避孕失败。没有证据表明,在 48 名未采取避孕措施的患者中,文化程度低是导致避孕措施遗漏的主要原因。

结论

在受孕后前 2 周无意中接触异维 A 酸不一定需要讨论终止妊娠,因为主要出生缺陷的风险似乎远低于此期间之后。尽管如此,鉴于改善自我信心、意外新伴侣和性活动以及对不孕的错误认知等心理社会因素,在使用异维 A 酸治疗时,仍需加强避孕措施的有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验